ArticleJournal of Alzheimer's disease : JAD2026
Associations of circulating resistin with Alzheimer's disease biomarkers and cognitive function in the preclinical stage of Alzheimer's disease.
Article in Journal of Alzheimer's disease : JAD, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
BackgroundResistin is a circulating protein linked to systemic metabolic disorders and inflammation, both of which can contribute to the pathogenesis of Alzheimer's disease (AD). However, the role of resistin during the preclinical stage of AD and its associations with amyloid-β and tau pathology have not been established.ObjectiveTo measure plasma resistin concentrations in cognitively normal older adults and examine its association with cerebrospinal fluid (CSF) AD biomarkers and neuropsychological measures.Methods155 (64 men and 91 women) cognitively normal (Clinical Dementia Rating 0) volunteers met all study criteria with 55 (29 men and 26 women) categorized as preclinical AD based on established CSF criteria. Plasma resistin concentrations were measured by immunoassay.ResultsSince plasma resistin concentrations were higher in men compared to women, all analyses were sex stratified. In men, plasma resistin concentrations were significantly higher in preclinical AD compared to biomarker negative controls and were associated with CSF concentrations of tau and p-tau
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.